Dendritic cell vaccines for leukemia patients

Expert Review of Anticancer Therapy

Volumn 7, Issue 3, 2007, Pages 275-283

  Schmitt, Anita ^a   Hus, Iwona ^b   Schmitt, Michael ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Medical University of Lublin Klinika Hematoonkologii i Transplantacji Szpiku AM w Lublinie   (Poland)

Author keywords

Acute myeloid leukemia; Chronic lymphocytic leukemia; Dendritic cell

Indexed keywords

DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; LEUKEMIA ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; CANCER CELL; CELL THERAPY; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DENDRITIC CELL; ERYTHEMA; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; INJECTION SITE INDURATION; LEUKAPHERESIS; LEUKEMIA; MICROORGANISM; REVIEW; T LYMPHOCYTE; VACCINATION;

ACUTE DISEASE; ANIMALS; ANTIGEN PRESENTATION; BONE MARROW CELLS; CANCER VACCINES; CELL ADHESION; CELL DIFFERENTIATION; CELLS, CULTURED; CLINICAL TRIALS; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ACTIVE; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOID; LYMPHOCYTE ACTIVATION; MICE; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR STEM CELLS;

EID: 33947641727     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.3.275     Document Type: Review

References (66)

1. Banchereau J, Brieè F, Caux C et al. Immunobiology of dendritic cells. Annu. Pev. Immunot 18, 767-811 (2000).
2. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 106, 271-274 (2001).
3. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat. Med 10, 475-480 (2004).
4. Mailliard RB, Dallal RM, Son YI, Lotze MT. Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigen. Immunol. Invest. 29, 177-185 (2000).
5. Bigotti G, Coli A, Castagnola D. Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade. Prostate 19, 73-87 (1991).
6. Tsuge T, Yamakawa M, Tsukamoto M. Infiltrating dendritic/Langerhans cells in primary breast cancer. Btrast Cancer Res. Treat. 59, 141-152 (2000).
7. Shimamura H, Cumberland R, Hiroishi K, Watkins SC, Lotze MT, Baar J. Murine dendritic cell-induced tumor apoptosis is partially mediated by nitric oxide. J. Immunother. 25, 226-234 (2002).
8. Kolb HJ, Mittemüller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462-2465 (1990).
9. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in aflogeneic chimeras. Blood 103, 767-776 (2004).
10. Greiner J, Döhner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia (AML) - definition of leukemia-associated antigens (LAAs) and current clinical protocols targeting LAAs. Haematologica 91, 1656-1664 (2006).
11. Hao JS, Shan BE. Immune enhancement and anti-tumour activity of IL-23. Cancer Immunol. Immunother. 55, 1426-1431 (2006).
12. Steinman RM, Adams JC, Cohn ZA Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen. J. Exp. Med. 141, 804-820 (1975).
13. + regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc. Natl. Acad. Sci. USA 103, 2758-2763 (2006).
14. Sallusto F, Lanzavocchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179, 1109-1118 (1994).
15. Jonuleit H, Kuhn U, Muller G et al. Pro-inflammatory cytokines and Prostaglandins induce maturation of potent imnumostimulatory dendritic cells under fetal calf scrum-free conditions. Eur. J. Immunol. 27, 3135-3142 (1997).
16. + monocytes to generate dendritic cells for cancer immunotherapy: a Phase I study. J Hematother. Stem Cell Res. 12, 515-523 (2003).
17. Berger TG, Feuerstein B, Strasser E et al. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in Cell Factories™. J. Immunol. Methods 268, 131-140 (2002).
18. Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Leukaemic dendritic cell vaccination for patients with acute myeloid leukaemia. Br. J Haematol 134, 445-446; Author reply 446-447 (2006).
19. Feuerstein B, Berger TG, Maczek C et al. A method fbr the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J. Immunol. Methods 245, 15-29 (2000).
20. Glaser A, Schuler-Thurner B, Feuerstein B et al. Collection of MNCs with two cell separators for adoptive immunotherapy in patients with stage IV melanoma. Tansfussion 41, 117-122 (2001).
21. Dzionek A, Sohma Y, Nagafune J et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen-capture and is a potent inhibitor of interferon-αL/β induction. J. Exp. Med. 194, 1823-1834 (2001).
22. Dzionek A, Fuchs A, Schmidt P et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165, 6037-6046 (2000).
23. Jiang W, Swiggard WJ, Heufler C et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375, 151-155 (1995).
24. Engering A, Geijtenbeek TB, van Vliet SJ et al. The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J. Immunol. 168, 2118-2126 (2002).
25. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5, 296-306 (2005).
26. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol. 17, 163-169 (2005).
27. + acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 94, 2048-2055 (1999).
28. Kohler T, Plettig R, Wetzstein W et al. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells 18, 139-147 (2000).
29. Choudbury A, Liang JC, Thomas EK et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous antileukemic T cell responses. Blood 93, 780-786 (1999).
30. Kufner S, Fleischer RP, Kroell T et al. Serum-free generation and quantification of functionlly active leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol, Immunother. 54, 953-970 (2005).
31. Li L, Reinhardt P, Schmitt A et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol. Immunother. 54, 685-693 (2005).
32. Li L, Schmitt A, Reinhardt P et al. Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Cancer Immun. 3, 8 (2003).
33. Li L, Giannopoulos K, Reinhardt P et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int. J. Oncot 28, 855-861 (2006).
34. Fröhling S, Skelin S, Liebisch C et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J. Clin. Oncol. 20, 2480-2485 (2002).
35. Kessler JH, Beekman NJ, Bres-Vloemans SA et al. Efficient identification of novel HLA-A 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med 193, 73-88 (2001).
36. Oka Y, Udaka K, Tsuboi A et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J. Immunol. 164, 1873-1880 (2000).
37. Greiner J, Ringhoffer M, Taniguchi M et al. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia (AML/CML). Int. J. Cancer 106, 224-231 (2003).
38. Weigel BJ, Panoskaltsis-Mortari A, Diers M et al. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Exp. Hematol 34, 1403-1412 (2006).
39. Lee JJ, Kook H, Park MS et al. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin. Apher. 19, 66-70 (2004).
40. Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res. 63, 4497-4506 (2003).
41. Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 195, 695-704 (2002).
42. Vuillier F, Maloum K, Thomas EK, Jouanne C, Dighiero G, Scott-Algara D. Functional monocyte-derived dendritic cells can be generated in chronic lymphocytic leukaemia. Br. J. Haematol. 115, 831-844 (2001).
43. Goddard RV, Prentice AG, Copplestone JA, Kaminski ER. In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids. Clin. Exp. Immunol, 131, 82-89 (2003).
44. Goddard RV, Prentice AG, Copplestone JA, Kaminski ER. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate. Clin. Exp. Immunol. 126, 16-28 (2001).
45. Kokhaei P, Adamson L, Palma M et al. Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors. Cytotherapy 8, 318-326 (2006).
46. Allgeier T, Garhammer S, Nossner E et al. Dendritic cell-based immunogens for B-cell chronic lymphocytic leukemia. Cancer Lett. 245, 275-283 (2007).
47. Suresh K, Fraser G, Scheid E, Leber B, Gauldie J, Foley R. Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate. Leuk. Lymphoma 47, 297-306 (2006).
48. Giannopoulos K, Li L, Bojarska-Junak A et al. Expression of RHAMM/CD168 and other tumor associated antigens in patients with B-cell chronic lymphocytic leukemia. Int. J Oncol. 29, 95-103 (2006).
49. Hus I, Roliski J, Tabarkiewicz J et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early stage B-cell chronic lymphocytic leukemia (B-CLL). Leukemia 19, 1621-1627 (2005).
50. Mahnke K, Schmitt E, Bonifaz L, Enk AH, Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol. Cell Biol. 80, 477-483 (2002).
51. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711 (2003).
52. Steinman RM, Hawiger D, Liu K et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann. NY Acad. Sci. 987, 15-25 (2003).
53. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM. Expansion of FOXP3 high regulatory T cells by human dendritic cells (DCs) invitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108, 2655-2661 (2006).
54. + regulatory T cells. Nat. Immunol. 4, 330-336 (2003).
55. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181-273 (2000).
56. Watson NF, Ramage JM, Madjd Z et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int. J. Cancer 118, 6-10 (2006).
57. Vollmer M, Li L, Schmitt A et al. Expression of human leucocyte antigens and costimulatory molecules on blasts of patients with acute myeloid leukaemia. Br. J. Haematol. 120, 1000-1008 (2003).
58. Fayad L, Keating MJ, Reuben JM et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97, 256-263 (2001).
59. + tumor cells in B chronic lymphocytic leukemia. Blood 91, 4273-4281 (1998).
60. Bruserud O, Ulvestad E. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels. Cancer Immunol. Immunother. 49, 377-387 (2000).
61. Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud O. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr. Cancer Drug Targets 5, 229-248 (2005).
62. Allavena P, Marchesi F, Mantovani A. The role of chemokines and their receptors in tumor progression and invasion: potential new targets of biological therapy. Curr. Cancer Therapy Rev. 12, 81-92 (2005).
63. Olsnes AM, Motorin D, Ryningen A, Zaritskey AY, Bruserud O. T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL 10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunol. Immunother. 55, 830-840 (2006).
64. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115, 739-746 (2005).
65. Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 199, 201-216 (2004).
66. Li L, Reinhardt P, Hus I et al. Dendritic cells (DC) generated from AML blasts express leukemia in the autologous host after DC vaccination. Blood 104, 1812 (2004).